Fairfax Media Limited

Felix Gold Ltd. engages in the gold exploration business. The company is headquartered in Brisbane, Queensland. The company went IPO on 2022-01-31. The firm is endowed Tintina Gold Province of Alaska in the United States. The firm holds an interest in gold projects within the Fairbanks District of the Tintina Gold Province in Alaska. The firm's projects include Treasure Creek Project, Grant-Ester Project and NE Fairbanks Project are situated in the Fairbanks Gold District of the Tintina Gold Province in Alaska. The Liberty Bell Gold Project is situated in the Bonniville gold district, covering approximately 115 kilometers (kms) southwest of Fairbanks, directly adjacent to the road and rail infrastructure that connects Fairbanks with Anchorage to the south. The project comprises 96 square kilometers (km2) tenure located adjacent to rail and road infrastructure, approximately 115 kms south of Fairbanks. Its subsidiaries include Felix Gold Treasure Creek Australia Pty Ltd, Felix Gold Liberty Bell Australia Pty Ltd and Felix Gold Ester Dome Australia Pty Ltd.

Felix Gold Ltd

Felix Gold Limited

QAU.AX was created on 2011-05-03 by BetaShares. The fund's investment portfolio concentrates primarily on gold commodities. The investment objective of the Fund is to provide an investment return, before fees and expenses, that closely tracks the performance of the price of gold bullion, with a currency hedge against movements in the AUD/USD exchange rate.

Betashares Gold Bullion Etf - Currency Hedged

Bionomics Ltd. is a clinical stage biopharmaceutical company. The firm is focused on developing allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with unmet medical needs. The firm operates in the drug development segment in Australia. The firm is advancing its lead drug candidate, BNC210, which is an oral, selective negative allosteric modulator of the a7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Its α7 Receptor Positive Allosteric Modulators (PAMs) pipeline is targeting cognitive dysfunction associated with Alzheimer’s disease and other central nervous system conditions. The company also includes a pre-clinical CNS pipeline that has two earlier-stage small molecule discovery programs targeting ion channels and representing opportunities for clinical programs.

Bionomics Limited

Living Cell Technologies Ltd. is a biotechnology company, which engages in the development of treatments for implanting healthy living cells to replace or repair diseased or damaged organs for life threatening diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-01. The firm is focused on discovering and developing treatments for conditions, such as diabetes and Parkinson's disease. The company operates in both Australia and New Zealand, being the research and development and product development into living cell technologies. The firm's product candidate includes NTCELL, an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells targeting Parkinson’s disease. Choroid plexus cells are naturally occurring support cells for the brain and secrete cerebrospinal fluid (CSF), which contains a range of factors that support nerve cell functions and protective enzymes that are crucial for nerve growth and healthy functioning. In NTCELL, the porcine choroid plexus cells are coated with LCT's technology IMMUPEL to protect them from attack by the immune system. The firm has completed two clinical trials of NTCELL in Parkinson's disease.

Living Cell Technologies Limited

Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. The company is headquartered in Melbourne, Victoria. The company went IPO on 2005-02-03. The Company’s lead drug compound, Trofinetide, is in Phase III clinical trial in the United States for Rett syndrome and has completed a Phase II clinical trial in Fragile X syndrome. The United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted Orphan Drug designation to Neuren for trofinetide in Rett syndrome. The firm has granted an exclusive license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide in North America while retaining all rights outside North America. The firm is preparing to initiate Phase II trials of its second drug candidate, NNZ-2591, for each of PhelanMcDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome.

Neuren Pharmaceuticals Limited

Patrys Ltd. engages in the commercialisation of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2007-07-13. The firm focuses on the development of antibody therapies for the treatment of cancer. The company is engaged in developing the treatment of Glioblastoma (GBM) and Triple Negative Breast Cancer (TNBC). The firm has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. The 3E10 antibody has several unusual biological properties not typically seen in antibodies, such as cancer targeting, blood-brain barrier, cell penetrating and inhibit deoxyribonucleic acid (DNA) damage repair. The firm has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. The company also uses the PAT-DX1 antibody to deliver nanoparticles carrying therapeutic payloads to the inside of cells. The firm is in the process of the first human clinical trial of PAT-DX1. Its two product candidates, PAT-DX2 and PAT-DX1-NP are under preclinical stage.

Patrys Limited

A2B Australia Ltd. engages in the provision of taxi charge account and related services to the taxi industry. The company is headquartered in Alexandria, New South Wales.  The firm provides taxi network services to taxi operators and drivers nationally in Australia. Its network services include taxi booking services, full taxi fit outs and repairs, vehicle financing and insurance, as well as driver training and education. The Company’s mobility Services are provided under brands, including 13cabs, Silver Service and Maxi Taxi. The company provides integrated booking, payment and safety technologies to taxi and private hire businesses under brands, including Cabcharge and Mobile Technologies International. Its Cabcharge provides payment terminals enabling drivers to process non-cash trip payments. Its Mobile Technologies International provides a vehicle monitoring platform. The firm also provides payment consulting, software, processing and terminals under brands, including EFT Solutions, Spotto, Giraffe and FlamingoPay.

A2B Australia Limited

ARN Media Ltd is a AU-based company operating in Media industry. The company is headquartered in Macquarie, New South Wales.  ARN Media Limited, formerly HT&E Limited, is an Australia-based broadcast and on-demand audio company. The firm owns approximately 58 radio stations across 33 markets plus 46 digital audio broadcasting (DAB+) stations nationwide. The firm's portfolio of brands includes KIIS Network, Pure Gold Network, CADA, Regional, iHeartRadio, and iHeartPodcast Network. KIIS Network includes KIIS stations, KIIS 1065, KIIS 101.1, and KIIS 97.3. Pure Gold Network delivers a combination of music, intelligent content and timeless entertainment to the Gen X audience. Its digital entertainment platform iHeartRadio app is an all-in-one radio, music streaming, podcast, and live events platform available to Australians in every state. Audiences can also access their favorite stations in Australia from ARN, Special Broadcasting Service (SBS) and stations from New Zealand and the United States. Its iHeartPodcast Network Australia is the preeminent podcast destination for creators, brands and audiences.

Arn Media Limited

A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 2975.21m in AUM and 200 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.

BetaShares Australia 200 ETF

Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

Vanguard Australian Shares Index ETF (ASX: VAS) seeks to track the performance of the ASX 300 index before account fees, expenses, and taxes. The index tracks the top 300 companies on the Australian Securities Exchange (ASX). These are mostly large and established Australian companies. It is a popular choice among passive individual investors who don't have the time or the expertise to actively invest in stocks.

Vanguard Australian Shares Index Etf

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

Vanguard MSCI Index International Shares Etf

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

VTS.AX was created on 2009-05-12 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard U.S. Total Market Shares Index ETF seeks to track the performance of the CRSP US Total Market Index, providing investors with exposure to a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.

Vanguard Us Total Market Shares Index Etf

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

The iShares S&P 500 ETF seeks to track the investment results of an index composed of large-capitalisation U.S. equities.

Back

Compare AU

Compare FXG vs. A200

Overview

Performance

Industry & Region

Top Holdings

Top Holdings